Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy

Trial Profile

Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Everolimus (Primary) ; Pazopanib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Feb 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
    • 08 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2019.
    • 07 Jun 2016 Results of a retrospective analysis of pazopanib from 4 phase I trials in patients with advanced sarcoma (NCT01339871, NCT01430572, NCT01454804, NCT01454804) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top